-

11:23:24 PM

GILD Stock News

GILD - Gilead Sciences, Inc.

06/03/23 1:30 PM

NYSE, Nasdaq : RCUS, GILD

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

RHEA-AI

neutral

06/03/23 1:30 PM

Nasdaq, NYSE : GILD, RCUS

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

RHEA-AI

neutral

06/01/23 8:34 AM

Nasdaq : GILD

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

Gilead Sciences, Inc. and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer...

RHEA-AI

negative

05/31/23 10:45 AM

NYSE : GILD

Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer

NORTHAMPTON, MA / ACCESSWIRE / May 31, 2023 / After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer. Yet many of his peers and friends discouraged him due to its many

RHEA-AI

neutral

05/26/23 1:00 AM

Nasdaq : GILD

covid-19

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury ® in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission will review the CHMP recommendation and, if adopted, Veklury will become...

RHEA-AI

neutral

05/25/23 4:05 PM

Nasdaq : GILD

conferences

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conference:. Jefferies Healthcare Conference on Wednesday, June 7 at 11:00am ET. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

RHEA-AI

neutral

05/25/23 9:40 AM

NYSE : GILD

How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story

NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead SciencesWhen LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. "A Gilead medicine saved the life of a loved one, so I was excited to begin a career here and to contribute in any way I could," LJ

RHEA-AI

very positive

05/17/23 8:30 AM

Nasdaq : GILD

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

Gilead Sciences, Inc. and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of...

RHEA-AI

negative

05/16/23 4:01 PM

Nasdaq : GILD

management

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’ s senior leadership team, effective May 30.. This press release features multimedia. View the full release here:...

RHEA-AI

very positive

05/16/23 8:00 AM

Nasdaq : GILD

Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million. The $50 million was contributed by new investors Kite, a Gilead Company,...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

GILD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.gilead.com
CeoDaniel O'Day
Security nameGilead Sciences, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees17000
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address333 Lakeside Dr
StateCalifornia
CityFoster City
Zip94404-1147
CountryUS
Phone16505743000

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.